Flowvium
العودة إلى المستكشف

AbbVie Inc.

ABBVleader

AbbVie is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. While Humira was once the world's best-selling drug, AbbVie has successfully navigated its patent cliff with Skyrizi and Rinvoq, which are on track to exceed Humira's peak revenue combined.

مشاركة:
⇄ Compare

المنتجات والإيرادات

حصة إيرادات المنتج

توزيع الإيرادات ($56.3B)

بيانات ثابتة (تحميل البيانات المالية…)

Immunology (45%)
Aesthetics/Neuroscience (25%)
Oncology (15%)
Eye Care & Other (15%)

تكوين القطاعات والعملاء الرئيسيون

تفاصيل المنتج

Skyrizi / Rinvoq35%

Next-generation immunology biologics replacing Humira revenue

Humira20%

Anti-TNF biologic for rheumatoid arthritis and autoimmune diseases (declining post-LOE)

Botox / Aesthetics25%

Allergan aesthetics portfolio including Botox, Juvederm, and CoolSculpting

علاقات سلسلة التوريد

المنافسون

Eli Lilly and Company

Immunology and oncology drugs

التأثير: Key therapeutic competitor

Regeneron Pharmaceuticals

Dupixent vs Skyrizi/Rinvoq

التأثير: Direct immunology competition

Pfizer Inc.

Broad pharmaceutical portfolio overlap

التأثير: Major pharma rival

السياق الكلي والسوقي

제약 / 바이오أخبار القطاع

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

المحفزات القادمة

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

إشارات مؤسسية

المؤسسةالإجراءالقيمةالربعتاريخ التقديم
BlackRockaccumulating$717M2024.062024-08-13↑
BlackRockreducing$272M2024.062024-08-13↓
BlackRockreducing$277M2024.062024-08-13↓
BlackRockreducing$21M2024.062024-08-13↓
BlackRockreducing$43M2024.062024-08-13↓
BlackRockaccumulating$507M2024.062024-08-13↑
BlackRockaccumulating$571M2024.062024-08-13↑
BlackRockaccumulating$8.8B2024.062024-08-13↑
BlackRockaccumulating$6.6B2024.062024-08-13↑
BlackRockaccumulating$563M2024.062024-08-13↑
BlackRockaccumulating$923M2024.062024-08-13↑
BlackRockreducing$346M2024.062024-08-13↓
BlackRockaccumulating$608M2024.062024-08-13↑
BlackRockreducing$6M2024.062024-08-13↓
BlackRockaccumulating$1.9B2024.062024-08-13↑
BlackRockreducing$83M2024.062024-08-13↓
BlackRockreducing$30M2024.062024-08-13↓
BlackRockaccumulating$643M2024.062024-08-13↑
BlackRockreducing$64M2024.062024-08-13↓
BlackRockreducing$11M2024.062024-08-13↓
BlackRockreducing$15M2024.062024-08-13↓
BlackRockreducing$399K2024.062024-08-13↓
BlackRockaccumulating$460M2024.062024-08-13↑
Vanguard Groupaccumulating$2.3B2025.122026-01-29↑
Vanguard Groupaccumulating$193M2025.122026-01-29↑
Vanguard Groupaccumulating$37.1B2025.122026-01-29↑
Vanguard Groupaccumulating$754M2025.122026-01-29↑
Vanguard Groupaccumulating$882M2025.122026-01-29↑
Vanguard Groupaccumulating$9M2025.122026-01-29↑
State Streetaccumulating$18.5B2025.122026-02-13↑
Wellington Managementaccumulating$3.1B2025.122026-02-17↑
Wellington Managementaccumulating$65M2025.122026-02-17↑
Wellington Managementreducing$32M2025.122026-02-17↓
Wellington Managementreducing$46M2025.122026-02-17↓
Wellington Managementreducing$24M2025.122026-02-17↓
Wellington Managementreducing$42M2025.122026-02-17↓
Wellington Managementreducing$37M2025.122026-02-17↓
Wellington Managementreducing$5M2025.122026-02-17↓
Wellington Managementaccumulating$93M2025.122026-02-17↑
FMR (Fidelity)accumulating$3.8B2025.122026-02-17↑
FMR (Fidelity)accumulating$280M2025.122026-02-17↑
FMR (Fidelity)accumulating$822M2025.122026-02-17↑
FMR (Fidelity)accumulating$41M2025.122026-02-17↑
FMR (Fidelity)accumulating$218M2025.122026-02-17↑
FMR (Fidelity)accumulating$25M2025.122026-02-17↑

آخر الأخبار

جارٍ تحميل الأخبار...

تحليل الذكاء الاصطناعي

انقر "احصل على تحليل AI" للحصول على تحليل سلسلة التوريد لـ AbbVie Inc..

معلومات الشركة

المقر الرئيسي

North Chicago, Illinois, USA

تأسست

2013

الموظفون

50,000+

الموقع الإلكتروني

abbvie.com

نظرة عامة على القطاع — 제약 / 바이오

أخبار القطاع

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

الموضوعات الرئيسية

  • •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
  • •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
  • •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성

المحفزات القادمة

  • ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
  • ◆MRNA 암백신 FDA BLA 제출 예정